Recently, Hengrui Pharmaceuticals' subsidiary Guangdong Hengrui Pharmaceuticals Co., Ltd. received the Notice of Approval for Clinical Trial of Drugs approved by the State Drug Administration, which approved HRS-9813 tablets, a Class 1 new drug, to carry out clinical trials for idiopathic pulmonary fibrosis (IPF).

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fibrotic interstitial lung disease of unknown cause, which ultimately leads to hypoxemia, respiratory failure and even death.IPF was included in the first batch of China's rare disease catalog in 2018, and in recent years, studies have shown that its incidence and prevalence are on the rise globally, and its prognosis is poor, and it is one of the diseases that researchers are currently working to overcome.

Currently, there are limited drugs approved for the treatment of IPF at home and abroad, and there are still deficiencies in terms of safety and patient compliance.There is still a huge unmet need for the treatment of IPF.

HRS-9813 Tablet is a Class 1 innovative drug independently developed by Hengrui Pharmaceuticals. Preclinical data of IPF efficacy in mice show that HRS-9813 can significantly improve lung function and pulmonary fibrosis after administration, with good safety. Upon inquiry, no similar drug has been approved for marketing at home and abroad.

https://mp.weixin.qq.com/s?__biz=MzU4Njc2Njc0NA==&mid=2247521473&idx=1&sn=90243ac89244d245892c017cbc86117c&chksm=fdf49436ca831d20c2f861806930d7205589aaaa28d8d53bc0e91f0817d48800d401346043e2&mpshare=1&scene=1&srcid=0705VEUASm8LW7osPjLpoZRB&sharer_shareinfo=d343173f766be6e972a926c379fcc69f&sharer_shareinfo_first=d343173f766be6e972a926c379fcc69f#rd